ERBB2 and neoplasm: The emerging of antibody-drug conjugates (ADCs) has changed treatment patterns of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).1 It is a new type of anti-tumor drug which combines monoclonal antibodies with cytotoxic drugs through linkers.